Amphastar Pharmaceuticals Inc (AMPH.OQ)
17 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2005||Chief Operating Officer, Chief Scientist and Chairman of the Board|
|43||2017||President, General Counsel, Director|
|70||2013||Chief Executive Officer, Chief Scientific Officer, Director|
|49||2016||Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc.|
|57||2015||Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc|
- BRIEF-Amphastar Announces Approval For Sodium Nitroprusside Injection, USP
- BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP
- BRIEF-Amphastar Pharma reports results for three months ended Sept
- BRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection
- BRIEF-Amphastar Pharmaceuticals reports Q2 earnings per share $0.04